# Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT

> **NCT04952350** · PHASE3 · UNKNOWN · sponsor: **Mansoura University** · enrollment: 220 (actual)

## Conditions studied

- Covid19
- SARS-CoV2 Infection
- COVID-19 Pneumonia

## Interventions

- **DRUG:** Atorvastatin 40 Mg Oral Tablet
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04952350
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-14
- **Primary completion:** 2021-11
- **Final completion:** 2022-04
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04952350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04952350, "Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04952350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*